Division of Surgical Oncology, Department of Surgery, University of California San Francisco.
Division of Surgical Oncology, Department of Surgery, University of California San Francisco.
Surg Clin North Am. 2024 Oct;104(5):965-974. doi: 10.1016/j.suc.2024.03.003. Epub 2024 Apr 23.
Pancreatic Cystic Neoplasms (PCN) represent a diverse group of tumors, some of which may progress to pancreatic cancer. Considering their high prevalence in the general population, the development of reliable biomarkers is crucial. The ideal biomarker will accurately diagnose the subtype of PCN and assess the risk of high-grade dysplasia or invasive cancer. Cyst fluid analysis has emerged as a promising approach to accomplish this goal, yet no single marker has yet gained unanimous support for routine inclusion in PCN evaluation.
胰腺囊性肿瘤（PCN）是一组具有异质性的肿瘤，其中一些可能进展为胰腺癌。鉴于它们在普通人群中的高患病率，开发可靠的生物标志物至关重要。理想的生物标志物将能够准确诊断 PCN 的亚型，并评估高级别发育不良或浸润性癌的风险。囊液分析已成为实现这一目标的有前途的方法，但尚无单一标志物获得一致支持，可常规纳入 PCN 评估。
